Literature DB >> 9386685

Preoperative intraaortic balloon pump enhances cardiac performance and improves the outcome of redo CABG.

J T Christenson1, P Badel, F Simonet, M Schmuziger.   

Abstract

BACKGROUND: Reoperative coronary artery bypass grafting (redo CABG) is associated with an increased operative risk compared with primary CABG. Because the hospital mortality in redo CABG is known to be influenced by poor left ventricular function (left ventricular ejection fraction < or = 0.40), unstable angina, and left main stem stenosis greater than or equal to 70%, a preoperative intraaortic balloon pump (IABP) support could be beneficial to improve the outcome in high-risk redo CABG.
METHODS: Between June 1994 and October 1996, 48 high-risk patients underwent redo CABG and were randomized into the following groups: group 1 (24 patients) who received preoperative IABP treatment on average 2 hours before cardiopulmonary bypass, and group 2 (24 patients) who received no preoperative IABP and served as controls. Mean age was 65 years and 90% (43 patients) were men. Forty-one patients had preoperative left ventricular ejection fraction less than or equal to 0.40 (85%), 38% (18 patients) had left main stem stenosis greater than or equal to 70%, and 54% (26 patients) had unstable angina preoperatively. Preoperative patient characteristics did not differ between the groups.
RESULTS: The time on cardiopulmonary bypass was shorter in group 1, 86 versus 110 minutes (p = 0.006). There were no hospital deaths in group 1, but four deaths occurred in the control group (p = 0.049). Cardiac index rose significantly preoperatively after introduction of the IABP in group 1. Cardiac index was significantly higher postoperatively in group 1 compared with group 2 and remained significantly higher during the first 24 hours after cardiopulmonary bypass. Significantly fewer patients in the IABP group had postoperative low cardiac output (4 versus 13 patients). Nine patients in group 2 required IABP support postoperatively for 4.1 +/- 1.7 days. Only 2 patients in group 1 needed IABP postoperatively, and their IABPs were successfully removed on the first postoperative day. The preoperative IABP-supported patients had a shorter intensive care unit stay, 2.4 +/- 0.8 days compared with group 2, 4.5 +/- 2.2 days (p = 0.007), as well as a shorter hospital stay. The preoperative IABP treatment was found to be cost-effective.
CONCLUSIONS: Preoperative treatment with IABP in high-risk redo CABG patients is an effective modality to prepare these patients to have their myocardial revascularization in an as nonischemic situation as possible, which resulted in a significantly lower hospital mortality, fewer instances of postoperative low cardiac output, and shorter stays in both the intensive care unit and the hospital.

Entities:  

Mesh:

Year:  1997        PMID: 9386685     DOI: 10.1016/S0003-4975(97)00898-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

1.  [Prophylactic intraaortic balloon pumping in high-risk cardiac surgery patients].

Authors:  D Metz; M Stiller; R-E Silber; H Kroll; H-S Hofmann; C Diez
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-29       Impact factor: 0.840

Review 2.  Preoperative intra aortic balloon pumps in patients undergoing coronary artery bypass grafting.

Authors:  Thomas Theologou; Mohamad Bashir; Arvind Rengarajan; Omar Khan; Tom Spyt; David Richens; Mark Field
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

3.  Temporal trends in the use of intraaortic balloon pump associated with percutaneous coronary intervention in the United States, 1998-2008.

Authors:  Hiren Patel; Anupama Shivaraju; Gregg C Fonarow; Hui Xie; Weihua Gao; Adhir R Shroff; Mladen I Vidovich
Journal:  Am Heart J       Date:  2014-06-06       Impact factor: 4.749

4.  Prophylactic intraaortic balloon counterpulsation in high-risk cardiac surgery: a survey of opinion and current practice.

Authors:  E Litton; A Delaney
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2013

Review 5.  Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.

Authors:  Susanne Unverzagt; Michael Buerke; Antoinette de Waha; Johannes Haerting; Diana Pietzner; Melchior Seyfarth; Holger Thiele; Karl Werdan; Uwe Zeymer; Roland Prondzinsky
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

Review 6.  Preoperative intra-aortic balloon pump to reduce mortality in coronary artery bypass graft: a meta-analysis of randomized controlled trials.

Authors:  Alberto Zangrillo; Federico Pappalardo; Roberto Dossi; Ambra Licia Di Prima; Marta Eugenia Sassone; Teresa Greco; Fabrizio Monaco; Mario Musu; Gabriele Finco; Giovanni Landoni
Journal:  Crit Care       Date:  2015-01-14       Impact factor: 9.097

7.  Prophylactic intra-aortic balloon counterpulsation in cardiac surgery: it is time for clear evidence.

Authors:  Philippe Grieshaber; Bernd Niemann; Peter Roth; Andreas Böning
Journal:  Crit Care       Date:  2014-11-29       Impact factor: 9.097

8.  The Effects of Intra-Aortic Balloon Pumps on Mortality in Patients Undergoing High-Risk Coronary Revascularization: A Meta-Analysis of Randomized Controlled Trials of Coronary Artery Bypass Grafting and Stenting Era.

Authors:  You-Dong Wan; Tong-Wen Sun; Quan-Cheng Kan; Fang-Xia Guan; Zi-Qi Liu; Shu-Guang Zhang
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

9.  Intensive care outcome of left main stem disease surgery: A single center three years' experience.

Authors:  Amr S Omar; Samy Hanoura; Yasser Shouman; Praveen C Sivadasan; Suraj Sudarsanan; Hany Osman; Abdul Rasheed Pattath; Rajvir Singh; Abdulaziz AlKhulaifi
Journal:  World J Crit Care Med       Date:  2021-01-09

10.  Propensity-matched analysis of the effect of preoperative intraaortic balloon pump in coronary artery bypass grafting after recent acute myocardial infarction on postoperative outcomes.

Authors:  Pey-Jen Yu; Hugh A Cassiere; Sophia L Dellis; Nina Kohn; Frank Manetta; Alan R Hartman
Journal:  Crit Care       Date:  2014-09-23       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.